Loading company…
Novamab develops inhaled nanobody drugs for respiratory, immune and tumor diseases.
Founded in 2017 and based in Shanghai, China, Novamab researches and develops nanobody drugs, including pipelines for respiratory, immune and tumor diseases. Its platforms support nanobody screening, CMC process development and inhaled drug development. In April 2026, it raised approximately CNY 300 million in Series B+ funding led by Qiming Venture Partners, with participation from Jiuyu Investment, Fuho Capital, Nanwan Baiao Fund, Jinyuan Kuntong Equity Investment Management, Zhaode Investment, Sunland and Guangdong Technology Financial Group.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in